Bristol-myers Squibb Compnay

Jianliang Shi

John E Macor

Lorin A Thompson, Iii

Yong-Jin Wu

Kenneth M Boy

Guanglin Luo

Carolyn Diane Dzierba

Amy C Hart

Jason M Guernon

Steven H Spergel

Jie Chen

Junqing Guo

William John Pitts

Yunhui Zhang

Michael E Mertzman

Richard Eric Olson

Sing-Yuen Sit

Scott Hunter Watterson

Lawrence R Marcin

Brian Lee Venables

Li Xu

Dmitry S Zuev

Murugaiah Andappan Murugaiah Subbaiah

Michael G Yang

Zili Xiao

David Bertil Frennesson

Mendi A Higgins

Matthew Reiser Patton

Xirui Hu

Andrew Charles Good

Jayakumar Sankara Warrier

Ramkumar Rajamani

Dalton King

Zhizhen Barbara Zheng

Srinivasan Thangathirupathy

F Christopher Zusi

Hua Gong

Imadul Islam

Carolyn A Weigelt

Michael F Dee

Michael C Mertzman

Lorin A Thompson Iii

Lorin A Iii Thompson

Iii Lorin A Thompson

Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Aminotriazolopyridines as kinase inhibitors

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Triazolopyridinyl compounds as kinase inhibitors

The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications. 

Aminopyrrolotriazines as kinase inhibitors

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein. 

Aminoimidazopyridazines as kinase inhibitors

Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX). 

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system. 

Selective NR2B antagonists

The present disclosure provides a series of compounds of the formula (I) 

Compounds for the reduction of &#x3b2;-amyloid production

Compounds for the reduction of beta-amyloid production

Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: 

The present disclosure provides a series of compounds of the formula (I) which reduce &#x3b2;-amyloid peptide (&#x3b2;-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by &#x3b2;-amyloid peptide (&#x3b2;-AP) production.

Bicyclic compounds for the reduction of beta-amyloid production

There is provided a series of substituted isophthalates of formula (I) or a stereoisomer thereof; or a pharmaceutically acceptable salt thereof, wherein W, R, Rand Ras defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by &#x3b2;-secretase and, more specifically, inhibit the production of A&#x3b2;-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to &#x3b2;-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

Isophthalates as beta-secretase inhibitors

There is provided a series of tetrahydroisoquinoline diaminopropane compounds of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R, Rand Rare as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by &#x3b2;-secretase and, more specifically, inhibit the production of A&#x3b2;-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to &#x3b2;-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

Substituted tetrahydroisoquinolines as &#x3b2;-secretase inhibitors

Growing community of inventors

Madison, CT, United States of America

Jianliang Shi